Read our latest insights into the Life Sciences industry.
Learn why requirements for plain-language summaries of clinical studies, aimed at a broad, non-technical audience, could create new risks for sponsors.
Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read August's edition from Kinapse.
Trust is a significant issue in Pharma. Blockchain could solve this problem and more in clinical trials, increasing transparency and saving time.
Learn how leading organisations are engaging patients from trial design to study close-out to create a holistic framework for improving patient experience.
Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read July's edition from Kinapse.
Blockchain could revolutionise the pharma supply chain, solving big issues in logistics, counterfeiting, and patient usage. Follow the link to find out how.
Threatened by innovative biotech organisations, Pharma companies need to accelerate their patient centricity initiatives or risk falling behind.
For the second consecutive year, Kinapse has ranked in the top 200 mid-market private companies with the fastest-growing overseas sales, according to the Sunday Times HSBC International Track 200.
Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read June's edition from Kinapse.
The life sciences consultancy has seen another year of double-digit growth, major client wins, new hires and promotions.
In the first of a four part blog series, we outline what blockchain is, and what applications it could present to the Pharmaceutical industry.
Fuelled by media scrutiny, drug affordability is becoming an increasingly powerful influence in market access decisions today. Learn how to overcome it.
Lean Biotechs and patients themselves are using new technology to revolutionise the patient experience. In order to keep up, Pharma needs to significantly accelerate and strengthen its value proposition in the digital space.
Your monthly compilation of regulatory news from around the globe. Follow the link to read March's edition from Kinapse.
Health Canada have drafted a guidance document relating to the planned public release of clinical trial documents, broadly in line with EMA Policy 0070. What are the key differences? How should your organisation prepare?
Plain language summaries of clinical study reports must be understood by lay readers and clinical experts. How should organisations strike the balance?